Casa Sollievo della Sofferenza is a private scientific research hospital in San Giovanni Rotondo, Italy, founded by Saint Pio of Pietrelcina, and administered by Vatican City.

During the past decade, Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 4 clinical trials were completed, i.e. on average, 21.1% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 1 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 29 trials, followed by "Gruppo Italiano Trapianto di Midollo Osseo" with 11 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored, "Institut de Recherches Internationales Servier" with 2 trials sponsored and "Fondazione Italiana Linfomi ONLUS" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza" #1 collaborator was "ADIR, a Servier Group company" with 2 trials as a collaborator, "Associazione Italiana di Immunogenetica e Biologia dei Trapianti (AIBT)" with 1 trials as a collaborator, "Azienda Policlinico Umberto I" with 1 trials as a collaborator, "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia" with 1 trials as a collaborator and "Biogen" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza" are "Chronic Myeloid Leukemia" (4 trials), "Leukemia" (4 trials), "Acute Lymphoblastic Leukemia" (3 trials), "Acute Promyelocytic Leukemia" (3 trials) and "Hematologic Diseases" (3 trials). Many other conditions were trialed in "Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza" in a lesser frequency.

Most popular intervention types in "Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza" are "Drug" (33 trials), "Other" (9 trials), "Procedure" (4 trials), "Biological" (2 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (3 trials), "Imatinib" (3 trials), "Doxorubicin" (2 trials), "Ibrutinib" (2 trials) and "Nilotinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza" are 49 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 34 completed trials in Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza, 2 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".